Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
Accounting for about 2% of cancers diagnosed worldwide, thyroid cancer has caused about 41,000 deaths in 2018. Despite significant progresses made in recent decades in the treatment of thyroid cancer, many resistances to current monotherapies are observed. In our complete review, we report all treat...
Main Authors: | Gheysen Laetitia, Saussez Sven, Journe Fabrice |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/4/830 |
Similar Items
-
New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer
by: Laetitia Gheysen, et al.
Published: (2021-05-01) -
Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives
by: Drazen Raucher, et al.
Published: (2018-12-01) -
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
by: Anne Perdrix, et al.
Published: (2017-12-01) -
Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
by: Yani Berckmans, et al.
Published: (2023-09-01) -
Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies
by: O, A. Bezborodova, et al.
Published: (2020-06-01)